- Regulation
- Technology
- Resources
Latest News
- Industry
21 USC 355(a)
-
FDA turns focus on biologics in spate of warning letters
The three letters point to an enforcement posture toward manufacturers marketing biologics derived from human placentas and umbilical cords.